Efficacy and safety of rasagiline in Chinese patients with early Parkinson's disease: a randomized, double-blind, parallel, placebo-controlled, fixed-dose study.

Transl Neurodegener · 2018 · PMC6282325 · PMID 30534374

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

A positive trend is shown if the estimated treatment difference is in favor of rasagiline for a two-sided test at the 25% level of significance.

also in 11,005 other papers

borderline significanceno p-value reported

The ratio of responders was also higher in the rasagiline group than in the placebo group (borderline significance), as was also reported in the TEMPO study [ 10 ].

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.